In April, Verve tweaked the development of the first PCSK9 inhibitor in its programme (VERVE-101) after a trial revealed ...

Other appointments to BIO's board for the 2025 through 2026 term include: Arcutis Bio's Frank Watanabe, named vice-chair; ...

Dr Lindborg shares her journey to her present role, the true potential shown in this new data for addressing unmet needs in ...

That challenge, of finding or building good, useable data sets, is also one of the biggest differentiators in an increasingly ...

Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

The annual conference of the Biotechnology Innovation Organization (BIO) is always an anticipated gathering where pharma and ...

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...